MEGAN TEMPLES: Open Payments
NPI 1750951273 · PARIS, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,985 in 128 payments from 21 companies in 2025. Trend: 2023 $1,920 · 2024 $2,799 · 2025 $2,985
Food & beverage: $2,985
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $374 |
| Bayer Healthcare Pharmaceuticals Inc. | 17 | $303 |
| Vifor Pharma, Inc. | 8 | $298 |
| Travere Therapeutics, Inc. | 7 | $261 |
| Otsuka America Pharmaceutical, Inc. | 9 | $244 |
| Amgen Inc. | 14 | $191 |
| Fresenius USA Marketing, Inc. | 11 | $176 |
| Novo Nordisk Inc | 7 | $156 |
| Novartis Pharmaceuticals Corporation | 6 | $151 |
| Ardelyx, Inc. | 7 | $148 |
Products named: Kerendia, Veltassa, FARXIGA, JYNARQUE, JARDIANCE, VELPHORO, IBSRELA, KRYSTEXXA.
Industry payments across IL — which companies pay providers there.
